Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study

Diabetes

Volumn 62, Issue 9, 2013, Pages 3218-3223

  Orchard, Trevor J ^a   Sun, Wanjie ^b   Cleary, Patricia A ^b   Genuth, Saul M ^c   Lachin, John M ^b   McGee, Paula ^b   Paterson, Andrew D ^d   Raskin, Philip ^e   Anbinder, Yefim ^f   Levy, Andrew P ^f  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; HAPTOGLOBIN;

ADOLESCENT; ADULT; ALBUMINURIA; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INTENSIVE CARE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; RISK FACTOR; URINALYSIS; URINARY EXCRETION; YOUNG ADULT; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; GENETICS; METABOLISM; PHYSIOLOGY;

ADOLESCENT; ADULT; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; HAPTOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; YOUNG ADULT;

EID: 84887517355     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0256     Document Type: Article

References (25)

1. de Boer IH, Sun W, Cleary PA, et al.; DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365:2366-2376
2. Pezzolesi MG, Skupien J, Mychaleckyj JC, Warram JH, Krolewski AS. Insights to the genetics of diabetic nephropathy through a genome-wide association study of the GoKinD collection. Semin Nephrol 2010;30:126-140
3. Makuc J, Petrovic D. A review of oxidative stress related genes and new antioxidant therapy in diabetic nephropathy. Cardiovasc Hematol Agents Med Chem 2011;9:253-261
4. Langlois MR, Delanghe JR. Biological and clinical significance of hapto-globin polymorphism in humans. Clin Chem 1996;42:1589-1600
5. Bowman BH, Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet 1982; 12:189-261, 453-454
6. Asleh R, Marsh S, Shilkrut M, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 2003;92:1193-1200
7. Levy AP, Asleh R, Blum S, et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 2010;12:293-304
8. Costacou T, Ferrell RE, Ellis D, Orchard TJ. Haptoglobin genotype and renal function decline in type 1 diabetes. Diabetes 2009;58:2904-2909
9. The Diabetes Control and Complications Trial (DCCT). Design and meth-odologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 1986;35:530-545
10. EDIC Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC). Design and implementation of a long-term follow-up of the Diabetes Control and Complications Trial Cohort. Diabetes Care 1999;22:99-111
11. Goldstein DE, Soeldner S, Cleary PA, Nathan DM; The DCCT Research Group. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 1987;33:2267-2271
12. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703-1720
13. Albers JW, Herman WH, Pop-Busui R, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010;33:1090-1096
14. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612
15. Hochberg I, Roguin A, Nikolsky E, Chanderashekhar PV, Cohen S, Levy AP. Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis 2002;161:441-446
16. Levy NS, Vardi M, Blum S, et al. An enzyme linked immunosorbent assay (ELISA) for the determination of the human haptoglobin phenotype. Clin Chem Lab Med 2013:1-8
17. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype-and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res 2005;96:435-441
18. Costacou T, Ellis D, Fried L, Orchard TJ. Sequence of progression of al-buminuria and decreased GFR in persons with type 1 diabetes: a cohort study. Am J Kidney Dis 2007;50:721-732
19. DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365: 2366-2376
20. Groop PH, Thomas MC, Moran JL, et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-1658
21. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010;53:2312-2319
22. Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 2008;57: 1702-1706
23. Simpson M, Snell-Bergeon JK, Kinney GL, et al. Haptoglobin genotype predicts development of coronary artery calcification in a prospective cohort of patients with type 1 diabetes. Cardiovasc Diabetol 2011; 10:99
24. Delanghe J, Langlois M, Duprez D, De Buyzere M, Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis 1999;145:287-292
25. Guthrie PA, Rodriguez S, Gaunt TR, Lawlor DA, Smith GD, Day IN. Complexity of a complex trait locus: HP, HPR, haemoglobin and cholesterol. Gene 2012;499:8-13